FDA
-
-
-
-
-
-
-
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
-
-
-
-
-
-
Mirum reports volixibat meets primary endpoint in cholangitis study
-
-
-
-
-
-
-
Mirum Pharmaceuticals (MIRM) PT Lowered to $132 at Citizens: Has Strong Momentum
-
-
-
-
-
-
-
Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics, Expanding Global Leadership in Rare Disease
-
-
-
-
-
-
-
Mirum Pharmaceuticals to acquire Bluejay Therapeutics for $620 million
-
-
-
-
-
-
-
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
-
-
-
-
-
-
-
Mirum Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
-
322,206 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

